Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Inclusion Criteria: * Histologically confirmed and immunophenotypically (CD20)-positive lymphoma at original diagnosis, progression, or relapse * Refractory to conventional therapy * First recurrent/refractory CD20-positive non-Hodgkin's lymphoma (NHL) allowed if ineligible for or refused regimens with known curative potential (high-dose chemotherapy plus bone marrow transplantation) (if available) * Second or third progression and/or recurrence of NHL * Second or third relapse/refractory CD20-positive Hodgkin's lymphoma * CD20-positive, post-transplantation lymphoproliferative lymphoma that is medically refractory (decreased immunosuppression) to rituximab and/or chemotherapy * Medically refractory, HIV-associated, CD20-positive NHL * Recurrent/refractory CD20-positive lymphoblastic lymphoma * Autologous peripheral blood stem cells (PBSC) collected, selected for a minimum of 2 x 10\^6 CD34-positive cells per kg, and cryopreserved before study entry * Meets one of the following criteria for bone marrow reserve: * Good marrow reserve, defined by both of the following: * No prior myeloablative stem cell transplantation (SCT) * No prior extensive radiotherapy, defined by any of the following: * Prior total body irradiation * Prior radiotherapy dose of 3,600 cGy or more to cranio-spinal axis * Prior radiotherapy to 50% or more of bone marrow * Poor marrow reserve, defined by either or both of the following: * Prior myeloablative SCT * Prior extensive radiotherapy * Performance status - Lansky 50-100% (age 10 and under) * Performance status - Karnofsky 50-100% (age 11 to 21) * At least 2 months * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 for patients with poor marrow reserve (transfusion independent) * Platelet count ≥ 150,000 for patients with good marrow reserve (transfusion independent) * Hemoglobin ≥ 8.0 g/dL (transfusion allowed) * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT ≤ 5 times ULN * Albumin ≥ 2 g/dL * Creatinine normal * Creatinine clearance or glomerular filtration rate ≥ 70 mL/min * Shortening fraction ≥ 27% by echocardiogram * Ejection fraction ≥ 50% by MUGA * No dyspnea at rest * No exercise intolerance * Oxygen saturation (SpO\_2) \> 94% by pulse oximetry (if there is a clinical indication for SpO\_2 assessment) * Not pregnant or nursing * Negative pregnancy test * No documented infection that is unresponsive to appropriate antibiotic, antiviral, or antifungal therapy * No grade 2 or greater CNS toxicity * Seizure disorder allowed if well controlled and on anticonvulsants * See Disease Characteristics * Recovered from prior immunotherapy * At least 1 week since prior antineoplastic biologic agents * Prior SCT allowed if the following criteria are met: * At least 60 days since prior SCT * Full hematopoietic reconstitution post-SCT * No evidence of active acute or chronic graft-versus-host disease if post- allogeneic SCT * No concurrent sargramostim (GM-CSF) * See Disease Characteristics * At least 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosourea) and recovered * See Disease Characteristics * Recovered from prior radiotherapy * No concurrent medications that would interact with the study drug